Umbricht
Christopher Umbricht, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20100260670 | ALTERNATIVE SPLICE VARIANT PATTERNS OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT) IN THYROID TUMORS TO DISTINGUISH BENIGN FROM MALIGNANT - This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the β sequence and the amount of TERT mRNA in the sample which comprises the β sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the β sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the β sequence indicates that the tumor is not malignant. | 10-14-2010 |
20110177971 | METHOD FOR DIAGNOSING THE STAGE OF A THYROID TUMOR - The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer. | 07-21-2011 |
Christopher B. Umbricht, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20120115804 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEOPLASIA - The invention features compositions and methods for characterizing the methylation status of the Vitamin D Receptor (VDR) in neoplasia (e.g., breast carcinoma), selecting an appropriate therapy, and treating the neoplasia (e.g., breast carcinoma). | 05-10-2012 |
20140371096 | COMPOSITIONS AND METHODS FOR CHARACTERIZING THYROID NEOPLASIA - The present invention features compositions and methods for characterizing thyroid lesions (e.g., benign follicular adenomas (FAs), papillary thyroid carcinomas (PTC) and follicular variant papillary thyroid carcinomas (FVPTCs)). | 12-18-2014 |
Christopher B. Umbricht, Towson, MD US
Patent application number | Description | Published |
---|---|---|
20100285979 | DIAGNOSTIC TOOL FOR DIAGNOSING BENIGN VERSUS MALIGNANT THYROID LESIONS - The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer. | 11-11-2010 |
Christopher Benedict Umbricht, Towson, MD US
Patent application number | Description | Published |
---|---|---|
20140221242 | GENOME-WIDE METHYLATION ANALYSIS AND USE TO IDENTIFY GENES SPECIFIC TO BREAST CANCER HORMONE RECEPTOR STATUS AND RISK OF RECURRANCE - To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided. | 08-07-2014 |
Daniel Umbricht, Zuerich CH
Patent application number | Description | Published |
---|---|---|
20140065610 | METHOD FOR PREDICTING CLINICAL BENEFIT IN THE TREATMENT OF NEURODEVELOPMENTAL, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS - An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI. | 03-06-2014 |
Daniel Umbricht, Zurich CH
Patent application number | Description | Published |
---|---|---|
20100041641 | USES OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 02-18-2010 |
20100249136 | ORGANIC COMPOUNDS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of Parkinson's Disease and associated disorders | 09-30-2010 |
20120309742 | USE OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 12-06-2012 |
20140187600 | USE OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 07-03-2014 |
Walter Umbricht, Gebenstorf CH
Patent application number | Description | Published |
---|---|---|
20120168244 | INDUSTRIAL PLANT WITH NOISE ATTENUATION HOOD - A noise-emitting industrial plant is provided, which is enclosed by a personnel-accessible noise attenuation hood for damping noise which issues from the plant. The noise attenuation hood includes a horizontal working platform which is provided for maintenance operations and/or repair work. The working platform is arranged at the noise attenuation hood in a foldout manner. | 07-05-2012 |